Allergan, Inc.
U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Parsippany
New Jersey
07054
United States
Tel: 1 (862) 261-7000
Website: http://www.allergan.com/
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
YEAR FOUNDED:
1948
LEADERSHIP:
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
CLINICAL TRIAL:
Please click here for clinical trial information.
PRODUCTS:
All Products
1187 articles with Allergan, Inc.
-
AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan
5/5/2020
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the U.S. Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie's pending acquisition of Allergan.
-
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to May 8, 2020
4/27/2020
AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.
-
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to May 1, 2020
4/20/2020
AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.
-
China Gives Greenlight to Allergan's XEN® Registration for the Surgical Management of Refractory Glaucoma
4/2/2020
XEN® Becomes the First Medical Product Approved by Using Real World Evidence in China
-
Allergan Earns ENERGY STAR® Partner of the Year - Sustained Excellence Award for the Seventh Consecutive Year
3/31/2020
Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR® Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR®'s highest honor.
-
The Allergan Foundation Donates $2.0 Million to Community Organizations on Front-Line of COVID-19 Response
3/30/2020
- Total 2020 Charitable Grants to Date Approach $13 Million, Including More than $3 million Devoted to Mental Health -
-
Allergan and Bausch Health Identified as the Top Companies Driving Therapeutic Innovation in IBS
3/26/2020
In an ongoing series of research conducted by KMK Consulting, Inc. covering Innovation & Customer Value, Allergan and Bausch Health (backed by its Salix division) were ranked as the top companies best poised to deliver therapeutic innovation in the IBS market. T
-
AbbVie and Allergan Sign Divestiture Consent Decree with FTC, Move Closer to Finalizing Merger
3/18/2020
The consent decree, including the proposed purchasers, remains subject to further review and approval by the Commissioners of the FTC. -
Allergan Declares Second Quarter 2020 Cash Dividend of $0.74 Per Ordinary Share
3/18/2020
Allergan plc (NYSE: AGN) today announced that its Board of Directors has declared a cash dividend of $0.74 per ordinary share for the second quarter of 2020. The dividend will be paid on the closing date of AbbVie's pending acquisition of Allergan, which remains subject to regulatory approval and customary closing conditions, or on June
-
Kybella Injections for Treating Double Chin & Submental Fat in NYC with Dr. Michele Green
3/11/2020
There has been an increase in advertising for Kybella from Allergan recently and in turn this has helped generate a lot more interest for the treatment for fat under the chin.
-
Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field.
-
Glaucoma is a progressive disease of the eye that can lead to irreversible vision loss and blindness.
-
Allergan Receives FDA Approval for DURYSTA™ (bimatoprost implant) the First and Only Intracameral Biodegradable Sustained-Release Implant to lower Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension Patients
3/5/2020
- DURYSTA™ lowered intraocular pressure in patients with open-angle glaucoma or ocular hypertension by approximately 30 percent from baseline in two Phase 3 studies -
-
Allergan and Editas Medicine Announce Dosing of First Patient in Landmark Phase 1/2 Clinical Trial of CRISPR Medicine AGN-151587 (EDIT-101) for the Treatment of LCA10
3/4/2020
Allergan plc announced the treatment of the first patient in the BRILLIANCE clinical trial of AGN-151587 at Oregon Health & Science University Casey Eye Institute, a world-recognized academic eye center.
-
On Tuesday, the European Commission gave the green light to the merger following the divestiture of an investigational autoimmune treatment.
-
AbbVie and Allergan Receive Final European Approval to Close Pending Transaction
3/3/2020
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that the European Commission has approved the divestiture of brazikumab, an investigational IL-23 inhibitor in development for autoimmune diseases, to AstraZeneca
-
Allergan to Present New Data for Investigational Bimatoprost Sustained-Release at American Glaucoma Society Annual Meeting
2/25/2020
Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a more than 70-year heritage in ophthalmology, will present new data from investigational Bimatoprost Sustained-Release (SR) at the Annual Meeting of the American Glaucoma Society (AGS) to be held in Washington, D.C.
-
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes to March 13, 2020
2/24/2020
AbbVie Inc. announced the extension of the expiration date of the offers to exchange any and all outstanding notes of certain series issued by Allergan Finance, LLC, Allergan, Inc., Allergan Sales, LLC and Allergan Funding SCS for new notes to be issued by AbbVie and the related consent solicitations being made by AbbVie on behalf of Allergan to adopt certain amendments to each of the indentures governing the Allergan Notes.
-
BTL Files Lawsuit against Allergan for False Advertising and Unfair Competition
2/20/2020
BTL Industries, Inc. announced it has filed a lawsuit against Allergan plc, Allergan USA, Inc., Allergan, Inc., and Zeltiq Aesthetics, Inc.
-
A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.